URGNのニュース
Results of the First Post-Commercial Utilization Review of JELMYTO Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer 2023/01/11 13:00:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights results from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyceal solution. This study evaluated 132 patients treated with JELMYTO from 15 high-volume academic and community
UroGen Pharma''s Return On Capital Employed Overview 2022/12/20 14:47:50 Benzinga
According to Benzinga Pro data, during Q3, UroGen Pharma (NASDAQ: URGN ) posted sales of $16.10 million. Earnings were up 3.22%, but UroGen Pharma still reported an overall loss of $25.83 million. In Q2, UroGen Pharma brought in $16.60 million in sales but lost $26.69 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a … Full story available on Benzinga.com
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) 2022/12/19 13:00:00 Investors Urogen
--If approved, UGN-102 would be the first non-surgical primary therapeutic to treat a subset of bladder cancer characterized by high recurrence rates and multiple surgeries PRINCETON, N.J. --(BUSINESS WIRE)--Dec. 19, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer 2022/12/02 00:00:00 Investors Urogen
--Results from this ongoing, non-interventional, rollover study were presented at the 23 rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego SAN DIEGO --(BUSINESS WIRE)--Dec. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer 2022/12/02 00:00:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today announced new data from the OLYMPUS registration trial designed to obtain long-term follow-up data on JELMYTO (mitomycin) for pyelocalyceal solution that shows median durability of response (DOR) of 28.9 months. The study (Abstract #158) was presented at
UroGen Pharma to Present at Upcoming Investor Conferences 2022/05/18 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C. Wainwright & Co. Global Investment Conference Wednesday, May 25 at 11:00 a.m. ET Jefferies Healthcare Conference Thursday, June 9 at 1:00 p.m. ET Webcasts of both the H.C. Wainwright & Co. and Jefferies presenta
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer 2022/05/16 18:50:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today highlights new data on real-world experience utilizing the antegrade approach via nephrostomy tube for administration of JELMYTO (mitomycin) for pyelocalyceal solution. This data adds to a growing body of evidence on the safety and efficacy profile of the
Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) 2022/05/16 05:31:13 ForexTV
Stock analysts at Oppenheimer increased their Q2 2022 EPS estimates for UroGen Pharma in a research report issued on Wednesday, May 11th. Oppenheimer analyst L. Gershell now expects that the company … Read Full Story at source (may require registration) The post Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) appeared first on ForexTV .
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript 2022/05/10 20:35:26 Seeking Alpha
UroGen Pharma Ltd. (NASDAQ:NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022, 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and…
UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M (NASDAQ:URGN) 2022/05/10 13:10:07 Seeking Alpha
UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09.Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M.
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022 2022/03/04 20:00:00 Investors Urogen
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference 2022/02/28 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th
UroGen begins phase 3 trial of UGN-102 to treat bladder cancer 2022/02/03 16:24:48 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Post Quarterly Sales of $17.20 Million 2021/12/22 21:08:42 Dakota Financial News
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE 2021/12/12 09:28:42 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []